Across TCGA pan-cancer cohorts, ATAD3C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATAD3C data layer compared with 26 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher ATAD3C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATAD3C expression acts as an unfavorable survival marker.
KICH, SCLC, and LUAD are the cancer types where ATAD3C Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.